MOZZ Research - First Half 2021, page-22

Interesting story which I find is somewhat inconsistent with my own personal experiences. Most vets will know of PPS but won't be so inclined to self-inject it for their own personal use.

Critically here though is that PPS has already been marketed as a DMOAD for dogs and horses.

Below is what Mozz has been banging on about.....trying to walk the collective HC herd of investors to the water.

PPS exhibit the following modes of action in dogs and horses:

1. Stimulates cartilage production – Stimulates chondrocytes to synthesize cartilage matrix
2. Improves the quantity and quality of synovial fluid – Stimulates synoviocyte biosynthesis of hyaluronan, improving both the quantity and molecular weight
3. Stimulates stem cell activity and cartilage cell differentiation – Promotes Mesenchymal precursor cell (MPC) proliferation and cartilage cell differentiation. Importantly, this is relevant with the frequency of MPCs elevated in arthritic cartilage
4. Increased blood supply and nutrition to the joint and subchondral bone – Mobilizes thrombi and fibrin deposits, lipids and cholesterol in synovial tissues and subchondral blood vessels in order to allow increased blood flow to key areas of the synovial joint.
5. Strong anti-inflammatory properties – The potent anti-inflammatory activities of PPS have been consistently demonstrated in different models of severe inflammation
6. Inhibits cartilage degrading enzymes – The collagenase catabolic enzyme is inhibited by the stimulation of tissue inhibitor metalloproteinase
7. Increased production of free radical scavenging enzymes – Stimulates free radical scavenging enzymes superoxide dismutase and lipase
8. Stimulates important growth factors that promote cartilage growth – Increases the production of the essential trophic factor for cartilage, insulin-like growth factor-1 (IGF-1), which stimulates incorporation of sulfate and encourages cartilage growth
9. Affinity for cartilage – The strong binding of the drug to cartilage protein results in therapeutic concentrations for up to 4 days (Data on file Biopharm Australia Pty Ltd)
10. Inhibits and modulates a range of noxious substances – such as pro-inflammatory mediators, bio-active amines such as: histamine, serotonin, superoxide free radical, enzymes such as elastase, hyaluronidase, cathepsins, THF-α converting enzyme (TACE) and proteins of the complement system which are implicated in the degradation of the cartilage matrix components

Source: http://www.cartrophen.com/for-vets/what-is-cartrophen-vet/


And from same source which is congruent with what we've already seen in human trial outcomes - Safety - http://www.cartrophen.com/for-vets/safety-and-efficacy/